BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, March 15, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 10, 2012
View Archived Issues
New auristatin derivatives for cancer prepared at Bayer Schering Pharma
Read More
Preclinical study identifies new Wnt signaling inhibitors that regulate cardiogenesis
Read More
Novel approach leads to discovery of NME that prevents tumor invasion
Read More
Silence Therapeutics and miRagen to collaborate on microRNA-based therapeutics
Read More
KAI Pharmaceuticals begins recruitment in second phase II study of KAI-4169
Read More
Ongoing phase I/II trial assesses combinations of letrozole with SAR-245408 and SAR-245409
Read More
Phase I/II data presented on SAR-245408-based combination regimens in metastatic breast cancer
Read More
New Evestra progesterone receptor inhibitor shows potential as breast cancer therapy
Read More
AstraZeneca patents new protein kinase inhibitors
Read More
Novel estrogen receptor-alpha modulators prepared by Aragon Pharmaceuticals
Read More
AstraZeneca and Pulmagen Therapeutics patent novel compounds for respiratory disorders
Read More
Clinical study of intranasally administered HIV vaccine fully enrolled
Read More
Scientists at Merck & Co. prepare new PRCP inhibitors
Read More
MDA provides financial support for preclinical work on TVN-102
Read More
New MAP kinase p38 inhibitors synthesized
Read More
Ista Pharmaceuticals begins phase II trial of combination nasal spray for seasonal allergic rhinitis
Read More
MHRA accepts Shire's MAA for once-daily ADHD therapy for review
Read More
Novel serine/threonine-protein kinase PAK inhibitors designed
Read More
Pfizer begins phase I study of PF-05280602
Read More
GSK and Theravance report data from phase III Relovair studies
Read More
Civitas Therapeutics reports results from phase I CVT-301 trial
Read More
Phase II trial of diabetes vaccine reaches full enrollment
Read More
Novavax provides update on joint venture in India
Read More
Astellas and Theravance terminate license agreement
Read More
Alnylam files ALN-TTR02 CTA with MHRA
Read More
